Agilent Technologies is set to acquire Biocare Medical for approximately $950 million, targeting completion by the fourth fiscal quarter of 2026 pending regulatory approvals. Biocare brings over 300 specialized immunohistochemistry antibodies and robust R&D capabilities, enabling Agilent to broaden its IVD antibody offerings and deepen its presence in clinical and research pathology laboratories.

The transaction is forecast to enhance Agilent’s revenue growth, improve margins and shift its revenue mix toward higher-margin, non-instrument products. Management expects the deal to be accretive to earnings per share roughly 12 months after closing and to support the development of new IVD antibodies by leveraging Biocare’s efficient product innovation.

Agilent’s shares have declined 5.6% over the past year and currently trade below both their 20-day and 50-day moving averages, with an RSI of 28 signaling an oversold condition. Analysts maintain a consensus buy rating with an average price target near $158.50, though several have recently trimmed targets to the $157–165 range.